Literature DB >> 9083235

Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research.

M G Petri1, J König, H P Moecke, H J Gramm, H Barkow, P Kujath, R Dennhart, H Schäfer, N Meyer, P Kalmar, P Thülig, J Müller, H Lode.   

Abstract

OBJECTIVE: To determine the epidemiological and clinical significance of invasive fungal infections in non-neutropenic patients in intensive care who stay longer than 10 days on the intensive care unit (ICU).
DESIGN: Prospective epidemiological multicenter study over a period of 11 months, based on strict clinical, bacteriological, serological and histological criteria.
SETTING: Six surgical and two medical ICUs units in five university and two municipal hospitals. PATIENTS: 435 non-neutropenic patients from medical and surgical ICUs with an ICU stay of more than 10 days.
MEASUREMENTS AND MAIN RESULTS: A new occurrence of invasive mycosis (3 sepsis/4 peritonitis/1 disseminated candidiasis), corresponding to the protocol conditions with onset after day 10 in the ICU, was detectable in 2.0% (95% confidence interval 0.85 to 3.8%) of the 409 patients who could be assessed. Candida species were identified as an infection-relevant pathogen in all cases. The most important risk factor for the development of an invasive mycosis was the onset of peritonitis by the day 11 in the ICU (odds ratio 11.3; p = 0.003). A fungal colonization was detected in 64% of patients (Candida species 56%, Aspergillus 4%, and other fungi). Six of 8 patients with an invasive mycosis died on the ICU; ICU mortality in patients with fungal colonization was 31% and in noncolonized patients 26%. Serological tests were not helpful clinically. The sensitivity was 88% for the Candida HAT (haemagglutination test) (threshold titer > 1:160), 100% for the Candida IFT (immunofluorescence test) (threshold titer > 1:80), and 50% for the Candida Antigen Test (Candtec Ramco, threshold titer > or = 1:8), and the specificity was 26, 6, and 73%, respectively. The specificity for the Aspergillus HAT (threshold titer > 1:10) was 29%.
CONCLUSIONS: Invasive mycoses are rare in non-neutropenic ICU patients, even after a longer stay in the intensive care unit; fungal colonization, on the other hand, is frequently detectable. The mortality of invasive mycosis--even with systemic antimycotic therapy--was high; the mortality in patients with fungal colonization was not significantly increased compared to that in noncolonized patients. The serological test procedures, Candida HAT, Candida IFT, and the Candida Ramco Antigen Test, had a low specificity and were not helpful in diagnosing relevant invasive mycosis.

Entities:  

Mesh:

Year:  1997        PMID: 9083235     DOI: 10.1007/s001340050334

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  31 in total

1.  Disseminated nosocomial fungal infection by Aureobasidium pullulans var. melanigenum: a case report.

Authors:  Giuseppe Bolignano; Giuseppe Criseo
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

Review 2.  Candida peritonitis: an update on the latest research and treatments.

Authors:  Herman Anthony Carneiro; Anastasios Mavrakis; Eleftherios Mylonakis
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

3.  Candida spp. colonization significance in critically ill medical patients: a prospective study.

Authors:  Pierre Emmanuel Charles; Frédéric Dalle; Hervé Aube; Jean Marc Doise; Jean Pierre Quenot; Ludwig Serge Aho; Pascal Chavanet; Bernard Blettery
Journal:  Intensive Care Med       Date:  2005-02-12       Impact factor: 17.440

4.  Epidemiology of nosocomial fungal infections in the National Center for Burns in Casablanca, Morocco.

Authors:  A Rafik; M Diouri; N Bahechar; A Chlihi
Journal:  Ann Burns Fire Disasters       Date:  2016-06-30

Review 5.  Host-Based Peripheral Blood Gene Expression Analysis for Diagnosis of Infectious Diseases.

Authors:  Zachary E Holcomb; Ephraim L Tsalik; Christopher W Woods; Micah T McClain
Journal:  J Clin Microbiol       Date:  2016-10-19       Impact factor: 5.948

Review 6.  What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients.

Authors:  Cristóbal León; Luis Ostrosky-Zeichner; Mindy Schuster
Journal:  Intensive Care Med       Date:  2014-04-10       Impact factor: 17.440

Review 7.  [Diagnosis and therapy of sepsis. Guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medicine].

Authors:  K Reinhart; F Brunkhorst; H Bone; H Gerlach; M Gründling; G Kreymann; P Kujath; G Marggraf; K Mayer; A Meier-Hellmann; C Peckelsen; C Putensen; M Quintel; M Ragaller; R Rossaint; F Stüber; N Weiler; T Welte; K Werdan
Journal:  Internist (Berl)       Date:  2006-04       Impact factor: 0.743

8.  Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?

Authors:  Rafael Zaragoza; Javier Pemán; Miguel Salavert; Angel Viudes; Amparo Solé; Isidro Jarque; Emilio Monte; Eva Romá; Emilia Cantón
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

9.  Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)).

Authors:  K Reinhart; F M Brunkhorst; H-G Bone; J Bardutzky; C-E Dempfle; H Forst; P Gastmeier; H Gerlach; M Gründling; S John; W Kern; G Kreymann; W Krüger; P Kujath; G Marggraf; J Martin; K Mayer; A Meier-Hellmann; M Oppert; C Putensen; M Quintel; M Ragaller; R Rossaint; H Seifert; C Spies; F Stüber; N Weiler; A Weimann; K Werdan; T Welte
Journal:  Ger Med Sci       Date:  2010-06-28

10.  Practices in non-neutropenic ICU patients with Candida-positive airway specimens.

Authors:  Elie Azoulay; Yves Cohen; Jean-Ralph Zahar; Maité Garrouste-Orgeas; Christophe Adrie; Pierre Moine; Arnaud de Lassence; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2004-05-18       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.